Literature DB >> 23917783

Impact of concurrent diagnostic level CT with PET/CT on the utilization of stand-alone CT and MRI in the management of head and neck cancer patients.

Rathan M Subramaniam1, Ankit Agarwal, Andrew Colucci, Regan Ferraro, Vasavi Paidpally, Gustavo Mercier.   

Abstract

PURPOSE OF THE REPORT: This study aims to determine if the expansion of a PET/CT service to include simultaneous contrast-enhanced CT with PET (PET/DCT) leads to a reduction of supplemental diagnostic CT (sCT) performed within a 6-month period centered around PET/CT for initial treatment planning of patients with head and neck cancers. PATIENTS AND METHODS: There were 91 patients with head and neck cancers who had a non-contrast-enhanced PET/CT with CT (PET/aCT), and 153 patients had a PET/DCT. We compared the utilization of sCT before and after PET/aCT or PET/DCT. Logistic regression analysis, unpaired t test, and analysis of variance were performed.
RESULTS: Among the 75 patients who had sCT scans in the 3 months before their PET/CT, 44 (58.7%) scans were performed in patients who had a PET/aCT and 31 (41.3%) scans were performed in patients who had a PET/DCT (P < 0.001). Among the 36 patients who had a CT in the 3 months after their baseline PET/CT, 23 (63.9%) were performed in patients who had a baseline PET/aCT and 13 (36.1%) were performed in patients who had a baseline PET/DCT (P < 0.001). The adjusted odds ratio for performing an sCT within 3 months before and after baseline PET/DCT scan as opposed to a PET/aCT scan was 0.24 (P < 0.001) and 0.31 (P < 0.01), respectively.
CONCLUSIONS: The opportunity to order simultaneous diagnostic CT imaging with PET/CT (PET/DCT) reduced the referrals for stand-alone CT neck imaging in the initial treatment plan of head and neck cancer patients when compared to a service that only offered the PET/CT scan with CT for attenuation correction (PET/aCT).

Entities:  

Mesh:

Year:  2013        PMID: 23917783     DOI: 10.1097/RLU.0b013e31829f8ca5

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  2 in total

1.  Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma.

Authors:  Yukako Ichimiya; Krishna Alluri; Charles Marcus; Simon Best; Christine H Chung; Rathan M Subramaniam
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

2.  Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.

Authors:  Christian Linz; Roman C Brands; Olivia Kertels; Alexander Dierks; Joachim Brumberg; Elena Gerhard-Hartmann; Stefan Hartmann; Andreas Schirbel; Sebastian Serfling; Yingjun Zhi; Andreas K Buck; Alexander Kübler; Julian Hohm; Constantin Lapa; Malte Kircher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-29       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.